menu
about us
company overview
corporate culture
manufacturing base
mah
drug development to commercialization
milestones
code of business ethics
services
services
providing reliable cdmo solutions with excellent quality and professional services
adc platform
overview
conjugation process
development
and optimization
drug product
formulation and
lyophilization process
analysis services
antibody manufacturing
adc drug substance
manufacturing
lyophilized drug
product manufacture
process and analytical method development
overview
cell culture
process development
purification process
development
drug product
formulation and
lophilization process
analysis services
gmp manufacturing
overview
drug substance
manufacturing
drug product
manufacturing
process characterization
/process validation
technology transfer
overview
technology transfer
quality
overview
quality control
quality assurance
regulatory affairs
overview
service and advantages
investor relations
company profile
corporate governance
announcements and circulars
the listed files
financial reports and esg reports
company promotion materials
investor relations query
investor relations journal
news & events
news
events
media attention
partner news
resources
technical articles
download center
join us
members of tot
join in tot
contact us
en
繁體
小9直播体育免费直播下载ios-小九体育直播
en
繁體
小9直播体育免费直播下载ios-小九体育直播
home
＜
news & events
partner news-小9直播体育免费直播下载ios
news
events
media attention
partner news
2022
2021
2022
2023
2022.09
09
congratulations! tot biopharm’s cdmo partner medilink therapeutics yl202 clinical trial application received default approval from the fda
recently, tot biopharm’s cdmo partner, medilink therapeutics, announced that its self-developed innovative antibody - drug conjugates (adc) yl202 has received default approval from the fda to conduct clinical trials for the treatment of advanced solid tum
«
1
»
the module is under construction
网站地图